Gilead Hit With Downgrades on Questions of Remdesivir Profit

(Bloomberg) -- A Gilead Sciences Inc. analyst advised investors to take their profits on the company’s $26.5 billion surge amid uncertainty on how the drugmaker could generate revenue from its Covi...